Side-by-side comparison
Bristol-Myers Squibb vs Merck & Co.
As of Sep 25, 2026, P/E is 13.8x for Bristol-Myers Squibb vs 119.0x for Merck & Co.; P/S is 2.6x for Bristol-Myers Squibb vs 5.5x for Merck & Co.; revenue growth is 3.1% for Bristol-Myers Squibb vs 4.6% for Merck & Co.; net margin is 18.9% for Bristol-Myers Squibb vs 4.8% for Merck & Co..
Key metrics
| Metric | BMY | MRK |
|---|---|---|
| Price | $62.86 | $148.78 |
| Market cap | $128.41B | $367.07B |
| P/E | 13.8x (#1) | 119.0x (#2) |
| P/S | 2.6x (#1) | 5.5x (#2) |
| Revenue growth | 3.1% (#2) | 4.6% (#1) |
| Operating margin | — | — |
| Net margin | 18.9% (#1) | 4.8% (#2) |
| Debt / equity | 1.89 (#2) | 1.22 (#1) |
| 1-year return | +42.5% (#2) | +89.4% (#1) |
| Research score | 71/100 (#1) | 51/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General